The trials underpinning initiation of perioperative blockers in patients with ischaemic heart disease having high risk surgery have largely been discredited, and the remaining evidence points to an increased risk of death. However, changes to the European guidelines have been slow. Graham Cole and Darrel Francis call for improvements to permit guideline experts to perform rapid amendments when required
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The principal support for the recommendation comes from two of the DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography) family of trials, which were discredited in 2011 because of misconduct. 2 Our 2013 meta-analysis of the remaining 11 credible randomised controlled trials indicates that perioperative initation of β blockade increases mortality by 27% (P=0.04, 95% confidence interval 1% to 60%). 3 The ESC did not alter its guidance as soon as the DECREASE trials were discredited in 2011 or after the publication of our meta-analysis reporting an increased risk of death, and in January 2014 we published an opinion article that included a rough calculation, using a formula from ESC experts, of the number of deaths that could result from an effect of this size across Europe. On 1 August 2014 the ESC reduced the strength of its recommendation to class IIb, 4 which means "usefulness/efficacy is less well established" but did not lower it to neutral or negative. We believe this would be appropriate for an intervention that increases mortality.
Here we describe how difficult it has been to challenge and change the guideline and question why the ESC guideline system prevented experts from acting more quickly and downgrading the recommendations further. We also highlight continued reliance on the DECREASE data, despite the guideline's expressed intention to exclude them. 4 
DECREASE influence
The DECREASE Study Group produced the research that drove the original recommendations and is still cited indirectly through meta-analyses 5 6 in the 2014 guidelines. The group conducted and published a family of six studies, beginning with the DECREASE I trial in 1999. 7 The six studies all have three authors in common and were led by Don Poldermans, then a professor at Erasmus University, Rotterdam, Netherlands. DECREASE I and DECREASE IV are both randomised trials of starting perioperative β blockade in surgical patients. 7 8 The trials showed a large and congruent reduction in mortality that is significantly different from the aggregate of all other trials of this intervention. 3 Poldermans was appointed chair of the ESC's perioperative task force and oversaw the construction of the guideline covering perioperative β blockers issued in 2009. 1 The first three authors of the guideline were authors of all six DECREASE studies. The bedrock of the recommendations was the two DECREASE trials. [7] [8] [9] In July 2011 serious questions about the integrity of the DECREASE trials led to an institutional investigation by Erasmus University into trials II to V. 10 11 DECREASE I was excluded from that investigation because it was more than 10 years old. 10 In November 2011, Erasmus University publicly reported that the DECREASE trial family was unreliable and contained fictitious data (box 1). Poldermans was dismissed for research misconduct. 2 The inquiry into the DECREASE IV trial of perioperative β blockade found no documentation that any patients had been prescribed a β blocker or that monitoring and up-titration had been done as described. 11 The assessment of outcome events was falsified and the adjudication committee was fictitious.
11
Cross checking the trial events against the real medical records showed that in a large number of cases the trial outcomes were fictional. 11 We believe that DECREASE I, too, should be considered insecure, both by association and because of its own red flags (box 2).
Our meta-analysis shows that, without the DECREASE trials, the data on perioperative β blockade show a significant increase in all cause mortality ( fig 1⇓) . 3 We found a 27% hazard reduction in non-fatal myocardial infarction but a 73% increase in risk of stroke and a 51% increase in risk of hypotension. 3 More good quality data are always welcome, but the significant increase in mortality already visible is not a sound basis for continuing to recommend initiation.
Secrecy
An ESC source who would not be named informed us that guideline signatories are covered by an agreement that events occurring within development of a guideline will be kept "secret and confidential." A secrecy agreement matching this description is accessible online. 16 There seems to be no clause permitting ESC experts to raise the alarm when needed, even to prevent loss of life. It also specifies that signatories "expressly agree that the existence of the Agreement and its whole content are deemed as strictly confidential." Whether there are other such restrictions may therefore never be known.
The ESC issued a press release on 23 November 2011, one week after the DECREASE trials were discredited. It did not rescind the recommendation based on the unreliable DECREASE data. Instead it concluded, "We are saddened by Prof Poldermans' situation and, although we are confident that our guidelines are supported by reliable data, we are carefully looking into the Guidelines for Pre-operative Cardiac Risk Assessment." 17 We need better ways to harness the expert skills of guideline contributors rapidly when source data are discredited.
Guidelines are reviewed every four years. 18 In March 2013 the ESC board agreed 19 that the guideline would be revised and published in summer 2014, effectively giving the 2009 guideline a lifespan of five years.
Our meta-analysis examining the efficacy of perioperative initiation of β blockers was published online in July 2013. 3 The next day the ESC issued a response that it was "currently revising these guidelines as announced in a previous statement in March 2013 taking into account this very complex scientific issue." 20 By that stage, a new head of the ESC guideline system had been appointed, and told journalists that the ESC was taking the meta-analysis "very seriously" and would "convene an urgent task force to decide whether further actions are required." The urgent task force concluded that decisions should be made on a "case by case basis." 21 The statement did not tell cardiologists that, when insecure data are set aside, there was a mortality increase.
False hope and a disappeared article
The European Heart Journal is the official journal of the European Society of Cardiology. We agreed to write a two part article for the news section of the journal on what readers could do to make clinical research more reliable. The first article explained that the magnitude of harm from research misconduct can be far greater than from clinical misconduct and used perioperative β blockade as an example. The second article presented practical steps to minimise harm from errors in clinical research.
The first article included an estimate of the number of excess deaths that may have occurred as a result of following the ESC guidelines over five years. We calculated this using the peer reviewed formula published in 2004 by the three key DECREASE leaders and guideline authors 1 22 to calculate the effect of perioperative β blockers on numbers of perioperative deaths in one country and applied it across Europe. This formula has not been criticised when used by those authors. Use of the hazard ratio for total mortality from our meta-analysis (1.27) in this formula 3 suggests that there may have been many deaths across Europe if perioperative β blockade was being initiated and was having the effect seen in the credible trials. We reminded readers that the calculation was only one possible estimate but suggested that around half of any resulting harm could have been prevented if practice had changed promptly.
Our first article (appendix 2) appeared online in the journal's CardioPulse section on 14 January 2014. As standard for this section, this was without peer review. But on 16 January friends notified us that all but the title of our article had disappeared (appendix 3). We received a letter from the journal's editor the following day explaining that the article had been temporarily retracted because it needed external peer review.
We believe that the new scientific content was insignificant; it involved multiplying three numbers: the number of operations carried out, their mortality, and the relative risk reduction by not initiating β blockade; a simple formula 22 approved by ESC experts. Eight days after the article was removed from the website, we received reviewer and editor recommendations that included merging the two articles into one. The peer review advised removing the figures and calculation.
Was the 2009 recommendation ever defensible after 2011?
While our resubmitted manuscript was undergoing review the European Heart Journal published, in response, an editorial 13 on 7 February 2014 criticising our disappeared work. It explained that our article had been retracted for peer review, stating that the journal had an absolute requirement for peer review of any item that made scientific statements. The editorial by senior EHJ experts certainly made scientific statements, using DECREASE I and introducing observational data 23 to oppose the findings of remaining randomised trials. We hope it was therefore peer reviewed.
The editorial said that "the Editor-in-Chief informed the author of one of the beta-blocker trials, who was heavily criticized in the article, that the European Heart Journal does not support the conclusions of this inadvertently published feature." The editorial does not identify the DECREASE author, but, soon afterwards, one of the trial authors became a deputy editor of the journal. 24 Our article did not criticise any author. It was 
DECREASE VI
• The only DECREASE study for which the full patient data were available for investigation
• Cross checking against those patients' actual medical records showed that, in at least 97% of cases, 11 their participation must have been fictional because they had not undergone stress echocardiography and surgery as specified. Moreover, there were no consent forms
DECREASE V
• The protocol and publication of this study described a five member panel analysing stress echo images and an independent adjudication committee to assess events such as myocardial infarction and renal failure. In reality, there was no record of any five member panel and no record of any stress echo images
• The elaborate description of patient assessment, for example, for myocardial infarction and renal failure, was falsified
DECREASE IV
• This study described an adjudication committee comprising a cardiologist, anaesthesiologist, and surgeon. However, this was fictitious and adjudications were made by one person
• No documentation that any patient had actually been prescribed any study drug
• Trial database listed many events but did not show any evidence (such as ECG or blood results indicating myocardial infarction). When the investigation cross-checked hospital records and discharge letters, there was very often no evidence of any such event.
DECREASE III
• No source data could be found by the investigation
• No written consent forms could be found
• The investigation panel therefore decided it could not investigate this study
DECREASE II
• One researcher claimed that the case record form was the primary document, but the principal investigator contradicted this, indicating that the case record form was merely "work notes" and the primary documents were different and had been mislaid
• Source data in the research database did not match the hospital's main clinical database
• "Incomprehensible" 11 explanation provided by principal investigator to investigation committee for the discrepancies
• Stress echo data in research database falsified: "in many cases the results from another test were entered in the database by a researcher"
DECREASE I
• Exempted from the 2011-12 Erasmus University investigations
Box 2: Concerns about DECREASE I 7 9
After the 2011 and 2012 Erasmus reports, the ESC press office, 12 European Heart Journal leadership, 13 and 2014 ESC guideline 4 continue to rely on DECREASE I as the only trial to reverse the aggregate result of other trials, which is that initiation of perioperative beta blockade increases mortality.
3 DECREASE I reports an improbably powerful 91% reduction 7 in death and myocardial infarction. Further details on the concerns below are available in appendix 1 on thebmj.com.
Information missing-When Erasmus University investigated 14 DECREASE I, the patient identities could not be traced for verification of baseline data and outcomes against clinical records. All members of the committee that assessed events and the committee that stopped the trial, named in the NEJM paper, now deny having had these roles.
14 The say they did not know they had been named in the NEJM. Erasmus could not carry out its planned forensic statistical analysis with the limited information provided by the authors. We suggest that the published papers contain enough meaningful data to decide on the reliability of the reports.
An unusually narrow distribution of heart rate-The range of heart rate of patients at all eight measurement points is so narrow that it is biologically implausible. Each of the eight probabilities is of the order of one in a quadrillion. 7 and the values given to meta-analysts 15 might be individually possible, they cannot both be true.
Variation between published DECREASE I values and those provided for meta-analysis-Though the values published in NEJM
Mathematical uncertainty about the primary endpoint-The odds ratio of the primary endpoint, death and myocardial infarction, is presented 9 with a confidence interval that is mathematically incompatible. Looking more deeply, both seem to be incorrect.
Confusion about which β blocker was used intravenously-The NEJM paper makes contradictory statements regarding whether the intravenous agent was metoprolol or bisoprolol. 7 Several inconsistencies in the tables-These include apparently fractional patients and a patient with minus 1 myocardial infarctions. The inconsistencies cannot be satisfactorily resolved without the raw data.
disappointing to read that the journal did not support our conclusion, which was: "With clinical research having far greater potential for harm, our responsibility to rectify errors is all the greater." If peer reviewers did approve the editorial, perhaps they, like everyone else, were unable to read our article (appendix 2) and therefore unable to check facts.
A simultaneous press release from the ESC 12 supported the journal's position. It defended the 2009 class I recommendation of perioperative β blockade based on three elements, each of which we consider to be unsound: use of DECREASE I, reliance on a recent observational dataset, 23 and challenging the validity of the POISE trial. 25 It argued for optimism that tweaking dose and timing might reverse the observed increase in deaths.
Our revised article was accepted on 16 June after four rounds of peer review and is awaiting publication.
Use of DECREASE I
The editorial emphasised the DECREASE I approach as reason to believe that perioperative initiation of β blockade might still be beneficial. We do not believe DECREASE I is sound (box 2 and appendix 1). Previously, the journal had issued notices of concern aiming at all articles published by Poldermans as first or last author. The DECREASE I paper in the European Heart Journal, which fits this description, 9 was missed. 26 The notice of concern bemoaned previous failure to recognise arithmetical impossibilities that delayed discovery of misconduct. Ironically, the omitted DECREASE I article is an example of exactly this.
Observational data used to support guidelines
The editorial cited an observational study to support the continued use of β blockade. 23 It is not clear why this observational study should provide more persuasive evidence than the remaining randomised trials, which show increased mortality. 3 Even this observational study could be read as showing an association between β blockers and higher mortality. Superficially, the observational study shows a 40 % higher relative risk of all cause mortality in patients who received a β blocker compared with those who did not (1.4% of 55 138 v 1.0% of 81 607 patients, P<0.0001). It does contain a propensity matching process that gives an opposite association, but the published tables contain what seem to be numerous typographical errors and, more importantly, the study is not a randomised controlled trial.
Editorial criticism of POISE
POISE is the largest of the remaining randomised trials in our meta-analysis. 25 The European Heart Journal argues that the dose of β blocker in the trial was too large and that this explains why it reduced "heart rate to an extent that did harm." 13 It describes dosing in the DECREASE trials as "more cautious." POISE and DECREASE used different drug molecules, so milligram comparisons are meaningless. Since the controlled release metoprolol used in POISE has a bioavailability of only 70-75% 27 28 compared with that of immediate release metoprolol, the trial's daily controlled release dose of 100-200 mg is broadly equivalent to 25-50 mg immediate release three times a day, which is a conventional dose. Dismissing the observed mortality increase as merely the result of the dose being "high" 13 or "very high"
12 is not safe. In fact, the POISE regimen reduced heart rate by 7 beats/min, 25 which contrasts with DECREASE I's reported 11-13 beats/min, 7 and DECREASE IV's 12 beats/min. 8 The reductions in heart rate do not suggest that the dosing used in POISE is excessive. 25 The European Heart Journal said POISE lacked "dose titration." 13 The ESC was concerned it had performed only "uptitration". 12 In fact, the POISE protocol specified that the dose could be reduced.
ESC position for 2014-2018
The ESC issued a new guideline in August. 4 The recommendations are softened to class IIb ("usefulness/efficacy is less well established"), but this is not enough. We believe that the ESC should reduce their recommendation to class III ("not recommended"), to reflect the significant increase in mortality in the credible randomised trials.
We are particularly concerned that it still draws on the DECREASE data, even though it states that it has excluded the trials (box 3). There remains a positive recommendation for starting β blockers for high risk surgery in patients with ≥2 risk factors or an anaesthetic status ≥3, which is supported by three references. 4 Two are not randomised studies. The third uses data from randomised trials but is a meta-analysis subgroup 6 that excludes POISE 25 and includes DECREASE I. 7 The POISE analysis, indicating that higher risk patients seemed most prone to net harm, was not mentioned. 25 The guidance also gives a favourable recommendation for starting β blockers in patients who have known ischaemic heart disease or myocardial ischaemia, again with three supporting references. Unfortunately, two of them 29 30 turn out to be the same controversial study that "failed to include an analysis by intention to treat and should not now influence perioperative practice." 31 The study omitted in-hospital deaths (which were twice as frequent with β blocker than without), [31] [32] [33] and, because it enrolled some patients already on β blockers, it was a mixed trial of initiation of β blockers in some and withdrawal in others. We also missed this second problem, not mentioned by the guideline, when doing our meta-analysis, 3 which perhaps should not have included this trial. The third supporting publication is a meta-analysis 5 that contains four mortality analyses, all of which are comprised only of the same controversial study 29 30 and DECREASE I. 7 Elsewhere the guideline states that the "benefit of beta blockade was found in five high risk surgery studies," which readers might interpret as five positive trials. When the reference 6 is checked, however, they comprise four trials with neutral results and DECREASE I.
Finally, the guideline states that the benefit of β blockade was found "in six studies using titration to targeted heart rate," which again readers might interpret as six positive results. In fact, four trials had zero events and the other two were DECREASE I and DECREASE IV. 
Further action needed
The newly appointed ESC president has declared that "Accountability and transparence will be my key words for Governance. An institution such as ESC needs a very clear Governance model, in order to be effective." 34 Secrecy during guideline construction is incongruous with this aim. It limits early problem solving and inhibits system-wide learning. Scientific leadership requires clear action to detect fraudulent research and deal with it decisively. The POISE authors set a good example 25 35 by publically and immediately striking out fraudulent data and making no effort to reassure or express sadness for the situation of fraudulent colleagues. We should all learn from this example.
We believe the ESC guideline system underutilises its most precious resource: the volunteered time of knowledgeable and respected professional leaders. We call for the guideline system to better harness this expertise by permitting them to hold their discussions openly. They must also be free to take urgent corrective action when studies that drive a recommendation are discredited.
If we have been misled by fraudulent data such as those in the discredited DECREASE trials, this is a great shame for patients who may have lost their lives. However, it is a far greater failing to respond incorrectly when the harm is recognised. 36 We need to reinvigorate guideline systems so that experts can act swiftly and openly to prioritise patient safety. 
